Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646708 | 0.87 | MTNR1A (0.46) | MTNR1AMTNR1BROCK2SLC2A1LMNA | |
| SCHEMBL3691395 | 0.85 | LMNA (0.39) | MTNR1AMTNR1BROCK2SLC2A1LMNA | |
| SCHEMBL5650079 | 0.76 | MTNR1A (0.46) | MTNR1AMTNR1BROCK2SLC2A1LMNA | |
| SCHEMBL3697078 | 0.73 | LMNA (0.40) | MTNR1AMTNR1BROCK2SLC2A1LMNA | |
| SCHEMBL3692223 | 0.72 | KCNH2 (0.40) | MTNR1AMTNR1BROCK2SLC2A1LMNA | |
| SCHEMBL5647894 | 0.71 | SLC2A1 (0.53) | SLC2A1KCNH2 | |
| SCHEMBL3685784 | 0.70 | MTNR1A (0.42) | MTNR1AMTNR1BROCK2SLC2A1LMNA | |
| SCHEMBL3689194 | 0.69 | KCNH2 (0.50) | SLC2A1KCNH2KDM4E | |
| SCHEMBL5652817 | 0.68 | KCNH2 (0.54) | MTNR1AMTNR1BSLC2A1KCNH2 | |
| SCHEMBL3685788 | 0.68 | ROCK2 (0.42) | MTNR1AMTNR1BROCK2SLC2A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | MTNR1A 3313/4885MTNR1B 2889/4885ROCK2 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.